Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 3:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Infant, Newborn, Diseases Clear all
Completed No phase listed Observational

Gait Parameters of Persons With Down Syndrome With and Without Orthotics Using GaitRite

NCT01390558
View directory record Official record
Conditions
Down Syndrome
Interventions
custom orthotics
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 80 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 1 Interventional

Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa

NCT00065455
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Vitamin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational

Gastrointestinal Microbiome Influence on the Development of Bronchopulmonary Dysplasia

NCT03229967
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
16S rRNA stool microbiome sequencing.
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
0 Days to 7 Days
Enrollment
197 participants
Timeline
2017 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational

Defining Immunodeficiency in Heterotaxy Syndrome: Pilot Study Data

NCT01929967
View directory record Official record
Conditions
Heterotaxy Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 12 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Jul 21, 2026, 3:16 PM EDT
Terminated Not applicable Interventional Results available

Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation

NCT02498444
View directory record Official record
Conditions
Single Ventricle
Interventions
Treprostinil
Drug
Lead sponsor
Stanford University
Other
Eligibility
1 Year to 18 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis

NCT04154293
View directory record Official record
Conditions
Congenital Ichthyosis
Interventions
Isotretinoin, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
9 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
Phoenix, Arizona • Palo Alto, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Terminated Phase 2 Interventional Results available

Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus

NCT02093221
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
180 mg/kg Alpha1-PI, 90 mg/kg Alpha1-PI, Placebo
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 35 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
36
States / cities
Tucson, Arizona • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders

NCT01050855
View directory record Official record
Conditions
Non Malignant Diseases, Immunodeficiencies, Hemoglobinopathies
Interventions
Reduced-Intensity Conditioning
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 25 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identification of Biomarkers in Spinocerebellar Ataxia 3

NCT03885167
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 3
Interventions
Specimen Collection
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jul 21, 2026, 3:16 PM EDT
Not yet recruiting Phase 1 Interventional

NAD Augmentation to Prevent or Reverse Alzheimer's Disease in People With Down Syndrome

NCT07278492
View directory record Official record
Conditions
Down Syndrome (DS)
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Not applicable Interventional Results available

Inhaled Nitric Oxide (iNO) as an Adjunct to Neonatal Resuscitation

NCT01220687
View directory record Official record
Conditions
Respiratory Distress Syndrome in Premature Infants, Very Low Birth Weight Baby
Interventions
iNO, Nitrogen
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
1 Minute to 2 Minutes
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jul 21, 2026, 3:16 PM EDT
No Longer Available No phase listed Expanded access

Compassionate Use of Triheptanoin (C7) for Inherited Disorders of Energy Metabolism

NCT01461304
View directory record Official record
Conditions
Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2), Mitochondrial Trifunctional Protein Deficiency, Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency, Glycogen Storage Disorders, Pyruvate Carboxylase Deficiency Disease, ACYL-CoA DEHYDROGENASE FAMILY, MEMBER 9, DEFICIENCY of, Barth Syndrome
Interventions
triheptanoin
Drug
Lead sponsor
Jerry Vockley, MD, PhD
Other
Eligibility
1 Month and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF-01913539] In Japanese And Western Healthy Subjects

NCT00825084
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2011 · Synced Jul 21, 2026, 3:16 PM EDT
Completed No phase listed Observational

The Use of a Distress Thermometer in a Pediatric Research Setting: An Exploratory Pilot Study

NCT00824278
View directory record Official record
Conditions
Cancer, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
7 Years to 21 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional

Anti-VEGF Therapy for Acute Thyroid Eye Disease

NCT04311606
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept, Sub-tenon injection of hyaluronidase (HA) alone
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 3 Interventional

Open-Label Phase III Long-Term Safety Trial of Liprotamase

NCT00449904
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
39
States / cities
Oakland, California • Denver, Colorado • Jacksonville, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

NCT02480114
View directory record Official record
Conditions
Malignant Head and Neck Neoplasm, Mucositis, Radiation-Induced Disorder
Interventions
Educational Intervention, Gabapentin, Pain Therapy, Quality-of-Life Assessment, Questionnaire Administration, Oxycodone/Acetaminophen, Hydrocodone/Acetaminophen, Fentanyl, Ibuprofen, Magic Mouthwash
Other · Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 1 Interventional

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

NCT00521248
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
buprenorphine, Oral morphine solution
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 2 Interventional Results available

Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.

NCT02272998
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
ponatinib hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
2
States / cities
Ann Arbor, Michigan • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)

NCT03569293
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo for Upadacitinib, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Single-Session "Empowered Relief" Class for Marfan Syndrome and Related Conditions

NCT05980104
View directory record Official record
Conditions
Chronic Pain, Marfan Syndrome, Vascular Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome
Interventions
Empowered Relief
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 21, 2026, 3:16 PM EDT
Completed Not applicable Interventional

Feasibility of a Goal-based Agenda Setting Intervention

NCT04696484
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Disease
Interventions
coopeRATE Prompt
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Denver, Colorado • Kansas City, Kansas • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jul 21, 2026, 3:16 PM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

NCT05418049
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 21, 2026, 3:16 PM EDT
Withdrawn Phase 1 Interventional

Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide

NCT04361058
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Myelodysplastic Syndrome Acute Myeloid Leukemia
Interventions
Nivolumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Jul 21, 2026, 3:16 PM EDT